Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and nervous system.
Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
These lead programs stem from the company’s proprietary platform for discovering and developing compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with synaptic plasticity. This mechanism has therapeutic potential in a number of diseases of the brain and nervous system with high unmet medical needs.